Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 17/20 | 0.45 |
| ▸ | BAZ2A | Q9UIF9 | 17/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | BRD9 | Q9H8M2 | 3/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | BRD2 | P25440 | 1/20 | 0.39 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25401220 | 0.85 | FNTA (0.51) | BAZ2BBAZ2AALDH1A1BRD4BRD2 | |
| SCHEMBL25402588 | 0.81 | LMNA (0.46) | ALDH1A1MAPTTP53 | |
| SCHEMBL29547188 | 0.80 | ALDH1A1 (0.40) | ALDH1A1MAPT | |
| SCHEMBL24510741 | 0.80 | BAZ2B (0.57) | BAZ2BBAZ2AALDH1A1BRD9TP53 | |
| SCHEMBL25399546 | 0.78 | BAZ2B (0.38) | BAZ2BBAZ2AALDH1A1BRD9BRD4 | |
| SCHEMBL25401668 | 0.78 | BAZ2B (0.62) | BAZ2BBAZ2ABRD9BRD4BRD2 | |
| SCHEMBL25400534 | 0.78 | MAPT (0.43) | ALDH1A1MAPTTP53 | |
| SCHEMBL26302021 | 0.78 | BAZ2B (0.54) | BAZ2BBAZ2ABRD9BRD4BRD2 | |
| SCHEMBL26302067 | 0.72 | BAZ2B (0.53) | BAZ2BBAZ2ABRD9TP53 | |
| SCHEMBL26302073 | 0.72 | BAZ2B (0.71) | BAZ2BBAZ2AALDH1A1BRD9BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4233864-B1 | COMPOSITION COMPRISING AN INDOLIZINE DERIVATIVE AND A CYCLIC DINUCLEOTIDE AS ACTIVE AGENTS | UNIV AJOU IND ACADEMIC COOP FOUND (KR) | 2025-02-12 | — | — | EP | disclosed |
| US-20230390319-A1 | INTERFERON GENE STIMULATOR COMPOSITION COMPRISING INDOLIZINE DERIVATIVE AS ACTIVE INGREDIENT | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2023-12-07 | — | — | US | disclosed |
| EP-4233864-A1 | INTERFERON GENE STIMULATOR COMPOSITION COMPRISING INDOLIZINE DERIVATIVE AS ACTIVE INGREDIENT | Ajou University Industry-Academic Cooperation Foundation (KR) | 2023-08-30 | — | — | EP | disclosed |
| WO-2022086260-A1 | INTERFERON GENE STIMULATOR COMPOSITION COMPRISING INDOLIZINE DERIVATIVE AS ACTIVE INGREDIENT | 아주대학교산학협력단 | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230390319-A1 | INTERFERON GENE STIMULATOR COMPOSITION COMPRISING INDOLIZINE DERIVATIVE AS ACTIVE INGREDIENT | STING1, IRF3, IFNG | BAZ2B 4487/4885BAZ2A 4020/4885ALDH1A1 3672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.